Fluoroquinolones in the management of tuberculosis

Progress in Respiratory Research

Volumn 40, Issue , 2011, Pages 51-60

  Singh, Kasha P ^a   Gillespie, Stephen H ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052917909     PISSN: 14222140     EISSN: 16623932     Source Type: Book Series    
DOI: 10.1159/000330110     Document Type: Article

References (79)

1. Hooper DC: Mechanisms of action of antimicrobials: Focus on fluoroquinolones. Clin Infect Dis 2001;32(suppl 1):S9-S15. (Pubitemid 32506740)
2. Gillespie SH, Kennedy N: Fluoroquinolones: A new treatment for tuberculosis? Int J Tuberc Lung Dis 1998;2:265-271. (Pubitemid 28168302)
3. Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau E: Mycobacterium tuberculosis DNA gyrase: Interaction with quinolones and correlation with antimycobacterial drug activity. Antimicrob Agents Chemother 2004;48:1281-1288. (Pubitemid 38405482)
4. Disratthakit A, Doi N: In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species. Antimicrob Agents Chemother 2010;54:2684-2686.
5. Ziganshina LE, Squire SB: Fluoroquinolones for treating tuberculosis. Cochrane Database Syst Rev 2008;1:CD004795.
6. Ruiz-Serrano MJ, Alcala L, Martinez L, Diaz M, Marin M, Gonzalez-Abad MJ, Bouza E: In vitro activities of six fluoroquinolones against 250 clinical isolates of Mycobacterium tuberculosis susceptible or resistant to first-line antituberculosis drugs. Antimicrob Agents Chemother 2000;44:2567-2568. (Pubitemid 30650920)
7. Blower SM, Chou T: Modeling the emergence of the 'hot zones': Tuberculosis and the amplification dynamics of drug resistance. Nat Med 2004;10:1111-1116. (Pubitemid 39424873)
8. Gillespie SH, Billington O: Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999;44:393-395. (Pubitemid 29425693)
9. Rodriguez JC, Ruiz M, Climent A, Royo G: In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis. Int J Antimicrob Agents 2001;17:229-231. (Pubitemid 32229902)
10. Peloquin CA, Hadad DJ, Molino LP, Palaci M, Boom WH, Dietze R, Johnson JL: Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother 2008;52:852-857. (Pubitemid 351358362)
11. Rodrigues C, Jani J, Shenai S, Thakkar P, Siddiqi S, Mehta A: Drug susceptibility testing of Mycobacterium tuberculosis against second-line drugs using the Bactec MGIT 960 system. Int J Tuberc Lung Dis 2008;12:1449-1455.
12. Duman N, Cevikbas A, Johansson C: The effects of rifampicin and fluoroquinolones on tubercle bacilli within human macrophages. Int J Antimicrob Agents 2004;23:84-87. (Pubitemid 38083315)
13. Shandil RK, Jayaram R, Kaur P, Gaonkar S, Suresh BL, Mahesh BN, Jayashree R, Nandi V, Bharath S, Balasubramanian V: Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: Evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007;51:576-582. (Pubitemid 46185275)
14. Veziris N, Truffot-Pernot C, Aubry A, Jarlier V, Lounis N: Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003;47:3117-3122. (Pubitemid 37229566)
15. Nuermberger EL, Yoshimatsu T, Tyagi S, O'Brien RJ, Vernon AN, Chaisson RE, Bishai WR, Grosset JH: Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004;169:421-426. (Pubitemid 38134824)
16. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH: Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004;170:1131-1134. (Pubitemid 39488628)
17. Cynamon M, Sklaney MR, Shoen C: Gatifloxacin in combination with rifampicin in a murine tuberculosis model. J Antimicrob Chemother 2007;60:429-432. (Pubitemid 47243900)
18. Nuermberger E, Tyagi S, Tasneen R, Williams KN, Almeida D, Rosenthal I, Grosset JH: Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother 2008;52:1522-1524. (Pubitemid 351522025)
19. Wise R, Honeybourne D: Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J 1999;14:221-229. (Pubitemid 29411262)
20. Zhanel GG, Noreddin AM: Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: Focus on respiratory infections. Curr Opin Pharmacol 2001;1:459-463. (Pubitemid 33593833)
21. Gumbo T, Louie A, Deziel MR, Parsons LM, Salfinger M, Drusano GL: Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling. J Infect Dis 2004;190:1642-1651. (Pubitemid 39411014)
22. Berning SE: The role of fluoroquinolones in tuberculosis today. Drugs 2001;61:9-18. (Pubitemid 32108319)
23. Sirgel FA, Donald PR, Odhiambo J, Githui W, Umapathy KC, Paramasivan CN, Tam CM, Kam KM, Lam CW, Sole KM, Mitchison DA: A multicentre study of the early bactericidal activity of anti-tuberculosis drugs. J Antimicrob Chemother 2000;45:859-870. (Pubitemid 30348958)
24. Pletz MW, De RA, Roth A, Neumann KH, Mauch H, Lode H: Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: A prospective, randomized study. Antimicrob Agents Chemother 2004;48:780-782. (Pubitemid 38280324)
25. Gosling RD, Uiso LO, Sam NE, Bongard E, Kanduma EG, Nyindo M, Morris RW, Gillespie SH: The bactericidal activity of moxifloxacin in patients with pulmonary tuberculosis. Am J Respir Crit Care Med 2003;168:1342-1345. (Pubitemid 37487329)
26. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, et al: Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2006;10:605-612. (Pubitemid 43845020)
27. Centre TR: Shortening short course chemotherapy: A randomised clinical trial for treatment of smear positive pulmonary tuberculosis with regimens using ofloxacin in the intensive phase. Indian J Tuberculosis 2002;49:12.
28. Rustomjee R, Lienhardt C, Kanyok T, Davies GR, Levin J, Mthiyane T, Reddy C, Sturm AW, Sirgel FA, Allen J, et al: A phase II study of the sterilising activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:128-138. (Pubitemid 351212403)
29. Conde MB, Efron A, Loredo C, De Souza GR, Graca NP, Cezar MC, Ram M, Chaudhary MA, Bishai WR, Kritski AL, Chaisson RE: Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: A double-blind, randomised, controlled phase II trial. Lancet 2009;373:1183-1189.
30. Burman WJ, Goldberg S, Johnson JL, Muzanye G, Engle M, Mosher AW, Choudhri S, Daley CL, Munsiff SS, Zhao Z, et al: Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006;174:331-338. (Pubitemid 44156613)
31. Dorman SE, Johnson JL, Goldberg S, Muzanye G, Padayatchi N, Bozeman L, Heilig CM, Bernardo J, Choudhri S, Grosset JH, et al: Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009;180:273-280.
32. MacKenzie WR, Heilig CM, Bozeman L, Johnson JL, Muzanye G, Dunbar D, Jost KC Jr, Diem L, Metchock B, Eisenach K, et al: Geographic differences in time to culture conversion in liquid media: Tuberculosis Trials Consortium study 28. Culture conversion is delayed in Africa. PLoS One 2011;6:e18358.
33. A controlled trial of a 4-month quinolonecontaining regimen for the treatment of pulmonary tuberculosis. http://clinicaltrials.gov/ct2/show/ NCT00216385?term=gatifloxacin+tuberculosis&rank=2.
34. Controlled comparison of two moxifloxacin containing treatment shortening regimens in pulmonary tuberculosis (REMox TB). http://clinicaltrials. gov/ct2/show/NCT00864383?term=moxifloxacin+tuberculosis&rank=1.
35. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, Fujiwara P, Grzemska M, Hopewell PC, Iseman MD, et al: American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-662.
36. Moadebi S, Harder CK, Fitzgerald MJ, Elwood KR, Marra F: Fluoroquinolones for the treatment of pulmonary tuberculosis. Drugs 2007;67:2077-2099. (Pubitemid 47524566)
37. WHO: Guidelines for the programmatic management of drug-resistant tuberculosis: Emergency update. Geneva, WHO, 2008.
38. Szklo A, Mello FC, Guerra RL, Dorman SE, Muzy-de-Souza GR, Conde MB: Alternative antituberculosis regimen including ofloxacin for the treatment of patients with hepatic injury. Int J Tuberc Lung Dis 2007;11:775-780. (Pubitemid 47056987)
39. Ho CC, Chen YC, Hu FC, Yu CJ, Yang PC, Luh KT: Safety of fluoroquinolone use in patients with hepatotoxicity induced by anti-tuberculosis regimens. Clin Infect Dis 2009;48:1526-1533.
40. Summary of product characteristics Avelox 400 mg. http://www.medicines. org.uk/emc/medicine/11841.
41. Summary of product characteristics Tavanic 500 mg tablets. http://www.medicines.ie/document.aspx?documentId=5377.
42. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM: Treatment outcomes of multidrugresistant tuberculosis: A systematic review and meta-analysis. PLoS One 2009;4:e6914.
43. Yew WW, Chan CK, Leung CC, Chau CH, Tam CM, Wong PC, Lee J: Comparative roles of levofloxacin and ofloxacin in the treatment of multidrug-resistant tuberculosis: Preliminary results of a retrospective study from Hong Kong. Chest 2003;124:1476-1481. (Pubitemid 37290060)
44. Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, Daru P, Rieder HL: Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med 2010;182:684-692.
45. Jacobson KR, Tierney DB, Jeon CY, Mitnick CD, Murray MB: Treatment outcomes among patients with extensively drug-resistant tuberculosis: Systematic review and meta-analysis. Clin Infect Dis 2010;51:6-14.
46. Cain KP, Nelson LJ, Cegielski JP: Global policies and practices for managing persons exposed to multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2010;14:269-274.
47. Management of persons exposed to multidrugresistant tuberculosis. MMWR Morb Mortal Wkly Rep 1992;41:61-71.
48. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M: Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002;167:131-136. (Pubitemid 34791519)
49. Takiff HE, Salazar L, Guerrero C, Philipp W, Huang WM, Kreiswirth B, Cole ST, Jacobs WR Jr, Telenti A: Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations. Antimicrob Agents Chemother 1994;38:773-780. (Pubitemid 24114017)
50. Alangaden GJ, Manavathu EK, Vakulenko SB, Zvonok NM, Lerner SA: Characterization of fluoroquinolone-resistant mutant strains of Mycobacterium tuberculosis selected in the laboratory and isolated from patients. Antimicrob Agents Chemother 1995;39:1700-1703.
51. Cheng AF, Yew WW, Chan EW, Chin ML, Hui MM, Chan RC: Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates. Antimicrob Agents Chemother 2004;48:596-601. (Pubitemid 38141721)
52. Von Groll A, Martin A, Jureen P, Hoffner S, Vandamme P, Portaels F, Palomino JC, da Silva PA: Fluoroquinolone resistance in Mycobacterium tuberculosis and mutations in gyrA and gyrB. Antimicrob Agents Chemother 2009;53:4498-4500.
53. Sreevatsan S, Pan X, Stockbauer KE, Connell ND, Kreiswirth BN, Whittam TS, Musser JM: Restricted structural gene polymorphism in the Mycobacterium tuberculosis complex indicates evolutionarily recent global dissemination. Proc Natl Acad Sci USA 1997;94:9869-9874. (Pubitemid 27408157)
54. Piton J, Petrella S, Delarue M, Andre-Leroux G, Jarlier V, Aubry A, Mayer C: Structural insights into the quinolone resistance mechanism of Mycobacterium tuberculosis DNA gyrase. PLoS One 2010;:e12245.
55. Cui Z, Wang J, Lu J, Huang X, Hu Z: Association of mutation patterns in gyrA/B genes and ofloxacin resistance levels in Mycobacterium tuberculosis isolates from East China in 2009. BMC Infect Dis 2011;11:78.
56. Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A, Jarlier V, Farinotti R, Veziris N: Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model. Antimicrob Agents Chemother 2010;54:4765-4771.
57. Kocagoz T, Hackbarth CJ, Unsal I, Rosenberg EY, Nikaido H, Chambers HF: Gyrase mutations in laboratory-selected, fluoroquinolone-resistant mutants of Mycobacterium tuberculosis H37Ra. Antimicrob Agents Chemother 1996;40:1768-1774. (Pubitemid 26277791)
58. Kam KM, Yip CW, Cheung TL, Tang HS, Leung OC, Chan MY: Stepwise decrease in moxifloxacin susceptibility amongst clinical isolates of multidrug-resistant Mycobacterium tuberculosis: Correlation with ofloxacin susceptibility. Microb Drug Resist 2006;12:7-11.
59. Aubry A, Veziris N, Cambau E, Truffot-Pernot C, Jarlier V, Fisher LM: Novel gyrase mutations in quinolone-resistant and -hypersusceptible clinical isolates of Mycobacterium tuberculosis: Functional analysis of mutant enzymes. Antimicrob Agents Chemother 2006;50:104-112. (Pubitemid 43042909)
60. Somasundaram S, Paramasivan NC: Susceptibility of Mycobacterium tuberculosis strains to gatifloxacin and moxifloxacin by different methods. Chemotherapy 2006;52:190-195. (Pubitemid 43882418)
61. Zhou J, Dong Y, Zhao X, Lee S, Amin A, Ramaswamy S, Domagala J, Musser JM, Drlica K: Selection of antibiotic-resistant bacterial mutants: Allelic diversity among fluoroquinolone-resistant mutations. J Infect Dis 2000;182:517-525. (Pubitemid 30651049)
62. Zhao X, Drlica K: Restricting the selection of antibiotic-resistant mutants: A general strategy derived from fluoroquinolone studies. Clin Infect Dis 2001;suppl 3:S147-S156. (Pubitemid 32835784)
63. Dong Y, Zhao X, Kreiswirth BN, Drlica K: Mutant prevention concentration as a measure of antibiotic potency: Studies with clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2000;44:2581-2584. (Pubitemid 30650925)
64. Blondeau JM, Zhao X, Hansen G, Drlica K: Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae. Antimicrob Agents Chemother 2001;45:433-438. (Pubitemid 32105277)
65. Sindelar G, Zhao X, Liew A, Dong Y, Lu T, Zhou J, Domagala J, Drlica K: Mutant prevention concentration as a measure of fluoroquinolone potency against mycobacteria. Antimicrob Agents Chemother 2000;44:3337-3343. (Pubitemid 33009492)
66. Gillespie SH, Basu S, Dickens AL, O'Sullivan DM, McHugh TD: Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates. J Antimicrob Chemother 2005;56:344-348. (Pubitemid 41158523)
67. Ginsburg AS, Grosset JH, Bishai WR: Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis 2003;3:432-442. (Pubitemid 36791119)
68. Van den Boogaard J, Semvua HH, Boeree MJ, Aarnoutse RE, Kibiki GS: Sale of fluoroquinolones in northern Tanzania: A potential threat for fluoroquinolone use in tuberculosis treatment. J Antimicrob Chemother 2010;65:145-147.
69. Sterling TR: The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: Potential pitfalls. Int J Tuberc Lung Dis 2004;8:1396-1400. (Pubitemid 40070244)
70. Long R, Chong H, Hoeppner V, Shanmuganathan H, Kowalewska-Grochowska K, Shandro C, Manfreda J, Senthilselvan A, Elzainy A, Marrie T: Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone- resistant tuberculosis. Clin Infect Dis 2009;48:1354-1360.
71. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C, Smith T, Hooper N, Maruri F, Warkentin J, et al: Fluoroquinolone resistance in Mycobacterium tuberculosis: The effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med 2009;180:365-370.
72. Chen TC, Lu PL, Lin CY, Lin WR, Chen YH: Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: A systematic review and meta-analysis. Int J Infect Dis 2011;15:e211-216.
73. Chiang CY: State of the art series on drugresistant tuberculosis: It's time to protect fluoroquinolones. Int J Tuberc Lung Dis 2009;13:1319.
74. Cox H, Ford N, Keshavjee S, McDermid C, von Schoen-Angerer T, Mitnick C, Goemaere E: Rational use of moxifloxacin for tuberculosis treatment. Lancet Infect Dis 2011;11:259-260.
75. Marra F, Marra CA, Moadebi S, Shi P, Elwood RK, Stark G, Fitzgerald JM: Levofloxacin treatment of active tuberculosis and the risk of adverse events. Chest 2005;128:1406-1413. (Pubitemid 41324425)
76. Chan ED, Laurel V, Strand MJ, Chan JF, Huynh ML, Goble M, Iseman MD: Treatment and outcome analysis of 205 patients with multidrugresistant tuberculosis. Am J Respir Crit Care Med 2004;169:1103-1109. (Pubitemid 38624789)
77. Park-Wyllie LY, Juurlink DN, Kopp A, Shah BR, Stukel TA, Stumpo C, Dresser L, Low DE, Mamdani MM: Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 2006;354:1352-1361.
78. Sekiguchi JI, Disratthakit A, Maeda S, Doi N: Characteristic resistance mechanism of DC-159a, a new respiratory quinolone, in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2011, E-pub ahead of print.
79. Ahmad Z, Minkowski A, Peloquin CA, Williams KN, Mdluli KE, Grosset JH, Nuermberger EL: Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrob Agents Chemother 2011;55:1781-1783.